Do analysts rate OXB or ABC?

Oxford Biomedica currently has a consensus target price of GBX 600.04, indicating a potential downside of 4.45%. Given Abcam's higher possible upside, analysts clearly believe Abcam is more favorable than Oxford Biomedica. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Abcam 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, OXB or ABC?

Abcam has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oxford Biomedica £168.74M 4.50 -£143.51M -£26.92 N/A Abcam £350.40M 0.00 N/A £0.06 N/A

Which has preferable earnings & valuation, OXB or GNS?

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oxford Biomedica £168.74M 4.50 -£143.51M -£26.92 N/A Genus £672M 2.10 £7.87M £71.00 29.94

Is OXB or GNS more profitable?

Genus has a net margin of 7.07% compared to Oxford Biomedica's net margin of -17.85%. Genus' return on equity of 9.70% beat Oxford Biomedica's return on equity. Company Net Margins Return on Equity Return on Assets Oxford Biomedica -17.85% -48.56% -12.67% Genus 7.07% 9.70% 3.31%

Do analysts prefer OXB or ERGO?

Oxford Biomedica currently has a consensus price target of GBX 600.04, indicating a potential downside of 4.45%. Given Ergomed's higher possible upside, analysts clearly believe Ergomed is more favorable than Oxford Biomedica. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Ergomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is OXB or ERGO more profitable?

Ergomed has a net margin of 9.87% compared to Oxford Biomedica's net margin of -17.85%. Ergomed's return on equity of 18.08% beat Oxford Biomedica's return on equity. Company Net Margins Return on Equity Return on Assets Oxford Biomedica -17.85% -48.56% -12.67% Ergomed 9.87% 18.08% 10.16%

Do analysts prefer OXB or SLN?

Oxford Biomedica currently has a consensus target price of GBX 600.04, suggesting a potential downside of 4.45%. Given Silence Therapeutics' higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Oxford Biomedica. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Oxford Biomedica (OXB) Competitors

GBX 628 -5.00 (-0.79%)

As of 12:28 PM Eastern

Compare

OXB vs. ABC, GNS, ONT, ERGO, and SLN

Should you buy Oxford Biomedica stock or one of its competitors? MarketBeat compares Oxford Biomedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oxford Biomedica include Abcam (ABC), Genus (GNS), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), and Silence Therapeutics (SLN). These companies are all part of the "biotechnology" industry.

How does Oxford Biomedica compare to Abcam?

Oxford Biomedica (LON:OXB) and Abcam (LON:ABC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

32.4% of Oxford Biomedica shares are owned by institutional investors. 43.3% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Oxford Biomedica currently has a consensus target price of GBX 600.04, indicating a potential downside of 4.45%. Given Abcam's higher possible upside, analysts clearly believe Abcam is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Abcam	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Abcam has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.50	-£143.51M	-£26.92	N/A
Abcam	£350.40M	0.00	N/A	£0.06	N/A

Abcam has a net margin of 0.00% compared to Oxford Biomedica's net margin of -17.85%. Abcam's return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Abcam	N/A	N/A	N/A

In the previous week, Oxford Biomedica had 2 more articles in the media than Abcam. MarketBeat recorded 2 mentions for Oxford Biomedica and 0 mentions for Abcam. Abcam's average media sentiment score of 0.00 beat Oxford Biomedica's score of -0.50 indicating that Abcam is being referred to more favorably in the news media.

Company	Overall Sentiment
Oxford Biomedica	Negative
Abcam	Neutral

Summary

Abcam beats Oxford Biomedica on 8 of the 13 factors compared between the two stocks.

How does Oxford Biomedica compare to Genus?

Oxford Biomedica (LON:OXB) and Genus (LON:GNS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Oxford Biomedica presently has a consensus target price of GBX 600.04, suggesting a potential downside of 4.45%. Genus has a consensus target price of GBX 3,216.67, suggesting a potential upside of 51.30%. Given Genus' stronger consensus rating and higher probable upside, analysts plainly believe Genus is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Oxford Biomedica has a beta of 1.096, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Genus has a beta of 0.896, suggesting that its share price is 10% less volatile than the broader market.

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.50	-£143.51M	-£26.92	N/A
Genus	£672M	2.10	£7.87M	£71.00	29.94

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 52.9% of Genus shares are owned by institutional investors. 43.3% of Oxford Biomedica shares are owned by company insiders. Comparatively, 0.7% of Genus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Oxford Biomedica had 1 more articles in the media than Genus. MarketBeat recorded 2 mentions for Oxford Biomedica and 1 mentions for Genus. Genus' average media sentiment score of 0.00 beat Oxford Biomedica's score of -0.50 indicating that Genus is being referred to more favorably in the news media.

Company	Overall Sentiment
Oxford Biomedica	Negative
Genus	Neutral

Genus has a net margin of 7.07% compared to Oxford Biomedica's net margin of -17.85%. Genus' return on equity of 9.70% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Genus	7.07%	9.70%	3.31%

Summary

Genus beats Oxford Biomedica on 11 of the 16 factors compared between the two stocks.

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Oxford Nanopore Technologies (LON:ONT) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Oxford Nanopore Technologies has a beta of 0.914, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.096, suggesting that its share price is 10% more volatile than the broader market.

19.6% of Oxford Nanopore Technologies shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by insiders. Comparatively, 43.3% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Oxford Biomedica has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£223.90M	5.40	-£175.21M	-£15.10	N/A
Oxford Biomedica	£168.74M	4.50	-£143.51M	-£26.92	N/A

In the previous week, Oxford Biomedica had 2 more articles in the media than Oxford Nanopore Technologies. MarketBeat recorded 2 mentions for Oxford Biomedica and 0 mentions for Oxford Nanopore Technologies. Oxford Nanopore Technologies' average media sentiment score of 0.00 beat Oxford Biomedica's score of -0.50 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Nanopore Technologies	Neutral
Oxford Biomedica	Negative

Oxford Nanopore Technologies presently has a consensus target price of GBX 218.60, indicating a potential upside of 75.76%. Oxford Biomedica has a consensus target price of GBX 600.04, indicating a potential downside of 4.45%. Given Oxford Nanopore Technologies' higher probable upside, equities analysts clearly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Oxford Biomedica has a net margin of -17.85% compared to Oxford Nanopore Technologies' net margin of -64.85%. Oxford Nanopore Technologies' return on equity of -29.43% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Summary

Oxford Biomedica beats Oxford Nanopore Technologies on 9 of the 16 factors compared between the two stocks.

How does Oxford Biomedica compare to Ergomed?

Oxford Biomedica (LON:OXB) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Oxford Biomedica has a beta of 1.096, indicating that its share price is 10% more volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 43.3% of Oxford Biomedica shares are owned by insiders. Comparatively, 18.2% of Ergomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Oxford Biomedica currently has a consensus price target of GBX 600.04, indicating a potential downside of 4.45%. Given Ergomed's higher possible upside, analysts clearly believe Ergomed is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Oxford Biomedica had 2 more articles in the media than Ergomed. MarketBeat recorded 2 mentions for Oxford Biomedica and 0 mentions for Ergomed. Ergomed's average media sentiment score of 0.00 beat Oxford Biomedica's score of -0.50 indicating that Ergomed is being referred to more favorably in the news media.

Company	Overall Sentiment
Oxford Biomedica	Negative
Ergomed	Neutral

Ergomed has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.50	-£143.51M	-£26.92	N/A
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

Ergomed has a net margin of 9.87% compared to Oxford Biomedica's net margin of -17.85%. Ergomed's return on equity of 18.08% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Ergomed	9.87%	18.08%	10.16%

Summary

Ergomed beats Oxford Biomedica on 9 of the 15 factors compared between the two stocks.

How does Oxford Biomedica compare to Silence Therapeutics?

Oxford Biomedica (LON:OXB) and Silence Therapeutics (LON:SLN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

In the previous week, Oxford Biomedica had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 2 mentions for Oxford Biomedica and 0 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 beat Oxford Biomedica's score of -0.50 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oxford Biomedica	Negative
Silence Therapeutics	Neutral

Oxford Biomedica currently has a consensus target price of GBX 600.04, suggesting a potential downside of 4.45%. Given Silence Therapeutics' higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Silence Therapeutics has a net margin of 0.00% compared to Oxford Biomedica's net margin of -17.85%. Silence Therapeutics' return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Silence Therapeutics	N/A	N/A	N/A

Silence Therapeutics has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.50	-£143.51M	-£26.92	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

32.4% of Oxford Biomedica shares are owned by institutional investors. 43.3% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Oxford Biomedica beats Silence Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Oxford Biomedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OXB vs. The Competition

Export

Metric	Oxford Biomedica	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£759.94M	£508.45M	£6.85B	£2.78B
Dividend Yield	4.57%	3.87%	2.66%	6.14%
P/E Ratio	-23.33	3.11	26.04	366.54
Price / Sales	4.50	6,785.72	550.39	85,951.69
Price / Cash	3.01	13.13	29.09	27.87
Price / Book	9.28	89.37	10.98	7.75
Net Income	-£143.51M	-£96.07M	£3.57B	£5.89B
7 Day Performance	5.02%	1.23%	3.06%	-1.01%
1 Month Performance	N/A	-0.19%	0.72%	-1.74%
1 Year Performance	98.73%	74.49%	36.82%	65.54%

Oxford Biomedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OXB Oxford Biomedica	0.7871 of 5 stars	GBX 628 -0.8%	GBX 600.04 -4.5%	+98.7%	£759.94M	£168.74M	N/A	891	Gap Down
ABC Abcam	N/A	N/A	N/A	N/A	£2.81B	£350.40M	20,433.33	1,650	Gap Up High Trading Volume
GNS Genus	2.6552 of 5 stars	GBX 2,178 -0.6%	GBX 3,216.67 +47.7%	+5.5%	£1.45B	£672M	30.68	480	Insider Trade
ONT Oxford Nanopore Technologies	N/A	GBX 114.20 -4.1%	GBX 218.60 +91.4%	-10.1%	£1.11B	£223.90M	N/A	1,281	Positive News
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:OXB) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oxford Biomedica (OXB) Competitors

OXB vs. ABC, GNS, ONT, ERGO, and SLN

How does Oxford Biomedica compare to Abcam?

Summary

How does Oxford Biomedica compare to Genus?

Summary

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Summary

How does Oxford Biomedica compare to Ergomed?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oxford Biomedica (OXB) Competitors

OXB vs. ABC, GNS, ONT, ERGO, and SLN

How does Oxford Biomedica compare to Abcam?

Do insiders and institutionals believe in OXB or ABC?

Do analysts rate OXB or ABC?

Which has preferable earnings and valuation, OXB or ABC?

Is OXB or ABC more profitable?

Does the media refer more to OXB or ABC?

Summary

How does Oxford Biomedica compare to Genus?

Do analysts recommend OXB or GNS?

Which has more risk and volatility, OXB or GNS?

Which has preferable earnings & valuation, OXB or GNS?

Do institutionals & insiders hold more shares of OXB or GNS?

Does the media favor OXB or GNS?

Is OXB or GNS more profitable?

Summary

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Which has more risk & volatility, ONT or OXB?

Do insiders and institutionals believe in ONT or OXB?

Which has stronger earnings & valuation, ONT or OXB?

Does the media refer more to ONT or OXB?

Do analysts prefer ONT or OXB?

Is ONT or OXB more profitable?

Summary

How does Oxford Biomedica compare to Ergomed?

Which has more volatility and risk, OXB or ERGO?

Do insiders and institutionals believe in OXB or ERGO?

Do analysts prefer OXB or ERGO?

Does the media favor OXB or ERGO?

Which has stronger valuation & earnings, OXB or ERGO?

Is OXB or ERGO more profitable?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Does the media favor OXB or SLN?

Do analysts prefer OXB or SLN?

Is OXB or SLN more profitable?

Which has stronger earnings and valuation, OXB or SLN?

Do insiders & institutionals hold more shares of OXB or SLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools